Daxor Corporation announced a new research letter in the Journal of the American College of Cardiology â Heart Failure validating the benefits of the Companyâs BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. The study, titled âDiscordant Pressure-Volume Trends During CardioMEMS Monitoring,â evaluated the correlation of pressure-volume profiles over two time periods in a series of heart failure (HF) patients who underwent CardioMEMS implantation to measure pressure, and direct measurement of total blood volume using Daxorâs blood volume analysis (BVA) diagnostic.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.83 USD | -1.89% | +0.34% | -8.02% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.02% | 42.44M | |
+2.65% | 12.65B | |
+17.89% | 10.1B | |
-2.15% | 5.43B | |
+4.54% | 5.14B | |
-2.48% | 5.08B | |
+27.90% | 4.85B | |
+22.11% | 4.49B | |
+0.72% | 3.95B | |
+2.04% | 3.85B |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation Announces New Research Letter About Heart Failure Validating the Benefits of BVA-100 Diagnostic in Optimizing Individualized Therapy